Shopping Cart
- Remove All
- Your shopping cart is currently empty
Ontuxizumab (MORAb-004) is a potent IgG1/κ monoclonal antibody targeting endomelanic acid with anti-tumor effects. It specifically targets endothelin (TEM-1 or CD248) and is used for the treatment of metastatic melanoma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $297 | In Stock | |
5 mg | $788 | In Stock | |
10 mg | $1,230 | In Stock |
Description | Ontuxizumab (MORAb-004) is a potent IgG1/κ monoclonal antibody targeting endomelanic acid with anti-tumor effects. It specifically targets endothelin (TEM-1 or CD248) and is used for the treatment of metastatic melanoma. |
In vitro | Ontuxizumab induces internalization of CD248 in a dose-dependent manner, with a reduction of 46% in surface CD248 on human dermal fibroblasts after 12 hours of treatment with concentrations ranging from 0 to 100 μg/mL[1]. |
In vivo | In human CD248 knock-in mice, Ontuxizumab demonstrates antitumor effects when administered at a dose of 50 mg/kg via intravenous injection, given five times a day for five consecutive days[1]. |
Alias | MORAb-004 |
Molecular Weight | 146.92 kDa |
Cas No. | 946415-62-9 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.